Genexine (Korea) Today
| 095700 Stock | KRW 4,080 15.00 0.37% |
PerformanceVery Weak
| Odds Of DistressLow
|
Genexine is trading at 4080.00 as of the 18th of March 2025, a 0.37 percent increase since the beginning of the trading day. The stock's open price was 4065.0. Genexine has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea.. The company has 20.55 M outstanding shares. More on Genexine
Moving against Genexine Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genexine Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genexine's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genexine or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology (View all Sectors) |
Genexine (095700) is traded on KOSDAQ in Korea and employs 123 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 318.55 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genexine's market, we take the total number of its shares issued and multiply it by Genexine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genexine has 20.55 M outstanding shares.
Genexine has accumulated about 27.8 B in cash with (12.75 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 687.14.
Check Genexine Probability Of Bankruptcy
Ownership AllocationGenexine has a total of 20.55 Million outstanding shares. Genexine secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genexine Ownership Details
Genexine Risk Profiles
Although Genexine's alpha and beta are two of the key measurements used to evaluate Genexine's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.91 | |||
| Standard Deviation | 2.5 | |||
| Variance | 6.26 | |||
| Risk Adjusted Performance | (0.18) |
Genexine Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genexine without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Genexine Corporate Management
Elected by the shareholders, the Genexine's board of directors comprises two types of representatives: Genexine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genexine. The board's role is to monitor Genexine's management team and ensure that shareholders' interests are well served. Genexine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genexine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| You Suh | Head Director | Profile | |
| Jungwon Woo | Chief Officer | Profile | |
| Sung CPA | CFO VP | Profile | |
| Kyu Kim | Ex Bus | Profile | |
| Jae Park | Ex Operation | Profile | |
| Young Sung | Chairman Founder | Profile | |
| JaiHyun Kwon | Director Transaction | Profile |
Other Information on Investing in Genexine Stock
Genexine financial ratios help investors to determine whether Genexine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genexine with respect to the benefits of owning Genexine security.